Enzymatic Sialylation of Therapeutic Proteins in Engineered E. coli

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for producing therapeutic proteins in bacterial systems face challenges in achieving efficient and complete sialylation, particularly in prokaryotic hosts like E. coli, where mammalian sialyltransferases often result in misfolded proteins and achieving human-like glycosylation is difficult due to competing endogenous enzymes and low efficiency of existing glycosylation systems.

Innovation Solution

The use of specific combinations of enzymes such as polypeptide N-acetylgalactosaminyltransferase, β-1,3-galactosyltransferase, UDP-Glc/GlcNAc 4-epimerase, disulfide bond isomerase, α-2,3-sialyltransferase, and α-2,6-sialyltransferase, either encoded on plasmids or integrated into the bacterial chromosome, to create an oxidizing environment in E. coli for in vivo sialylation of therapeutic proteins, enabling complete monosialylation and disialylation of human proteins.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If mammalian cellular hosts (CHO and HEK cells) are used to produce therapeutic proteins, then proper folding and human-like post-translational modifications can be achieved, but production cost increases and growth speed decreases

Engineering Contradiction:

Improveglycosylation homogeneityVSAvoidproduction efficiency

Core Design Contradiction:

Manufacturing precisionVSProductivity

Solution Approach 1:

The patent uses engineered E. coli as an intermediary host that has been modified to express mammalian glycosylation enzymes. This intermediary system bridges the gap between simple bacterial production and complex mammalian post-translational modification capabilities, enabling cost-effective production of glycosylated therapeutic proteins without requiring expensive mammalian cell culture infrastructure

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent fundamentally changes the host organism parameter from mammalian cells to engineered bacteria, while simultaneously changing the enzymatic capability parameter by introducing heterologous glycosylation enzymes. This parameter transformation allows achieving mammalian-like glycosylation in a prokaryotic system, resolving the contradiction between production efficiency and glycosylation quality

Inventive Principle:

Principle #35Parameter changes

2Productivity

If E. coli is used as host for production of mammalian proteins, then production efficiency improves, but proteins are produced as insoluble inclusion bodies requiring refolding with low yields

Engineering Contradiction:

Improveproduction efficiencyVSAvoidprotein solubility

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies local quality by creating specific conditions within the E. coli periplasm that favor proper protein folding and solubility. The periplasmic environment, with its oxidizing conditions and specific chaperone systems, provides a localized favorable environment for mammalian protein folding, preventing inclusion body formation while maintaining high production efficiency

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent performs preliminary action by engineering the E. coli host system in advance to express appropriate chaperones and foldases, and by designing signal sequences that direct proteins to the periplasm before the actual protein production occurs. This preliminary preparation ensures that when mammalian proteins are produced, the cellular environment is already optimized for their proper folding and solubility

Inventive Principle:

Principle #10Preliminary action

3Adaptability or versatility

If E. coli glycosylation systems are engineered, then sialylation capability is introduced, but efficiency remains low due to competing endogenous enzymes

Engineering Contradiction:

Improveglycosylation capabilityVSAvoidsialylation efficiency

Core Design Contradiction:

Adaptability or versatilityVSProductivity

Solution Approach 1:

The patent applies the taking out principle by removing or suppressing the competing endogenous E. coli glycosylation pathways that interfere with mammalian-style sialylation. By eliminating these interfering native enzymes and pathways, the system achieves high efficiency in producing the desired sialylated glycoforms without competition from bacterial glycosylation reactions

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent merges multiple glycosylation enzyme activities into a coordinated system within the engineered E. coli. By combining expression of polypeptide N-acetylgalactosaminyltransferase, β-1,3-galactosyltransferase, and sialyltransferases under controlled conditions, the system achieves efficient multi-step glycosylation and sialylation processes that overcome the limitations of individual enzyme expressions

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for the efficient production of sialylated therapeutic proteins with high glycosylation yields, improving pharmacokinetic properties by achieving up to 85% sialylation and disialylation of target proteins like GB1-IFNα2b, demonstrating a robust and flexible system for producing human-like O-glycans in bacterial expression systems.